Pharma Marketing Network

This article summarizes results from Manhattan Research's recently released survey: ePharma Physician v3.0: The Future of Pharmaceutical eMarketing, which focused on the adoption of emerging technologies by an early adopter physician audience. This audience is not small and cannot be ignored! Data are presented showing which online marketing programs are considered most effective by this group of physicians and what they desire as the optimal channel mix for marketing programs.

CBI's Forum on Pharmaceutical Branding, August 14-15, 2003, in Princeton, NJ brings together marketing, product, brand and business development leaders to share their experiences and insights into how you can best position your brand in the market place.

Pharmaceutical Education Associates presents Understanding the OIG's Compliance Program Guidance for Pharmaceutical Manufacturers conference.

This article reviews a presentation made by David Ormesher, CEO of closerlook, inc. at the recent CBI eDetailing Conference in which he said, The future of eDetailing is physician relationship management. The benefits of creating long-term relationships include brand loyalty, detailed customer intelligence and sales integration with the field force.

In this presentation Sue Ramspacher, Senior Vice President, Portfolio Management, Market Measures/Cozint, summarized results of her firm's 2002 DTC Monitor study.

In this presentation Sue Ramspacher, Senior Vice President, Portfolio Management, Market Measures/Cozint, summarized results of her firm's 2002 DTC Monitor study.

This presentation put out-of-the-box marketing ideas such as Permission Marketing into the context of pharmaceutical promotions. Dr. Vanderveer -- the presenter -- posed important questions that pharmaceutical market researchers must ask themselves, especially in light of two looming pharmaceutical marketing crises: Decreasing ROI and Fewer Blockbuster Drugs.

This presentation put out-of-the-box marketing ideas such as Permission Marketing into the context of pharmaceutical promotions. Dr. Vanderveer -- the presenter -- posed important questions that pharmaceutical market researchers must ask themselves, especially in light of two looming pharmaceutical marketing crises: Decreasing ROI and Fewer Blockbuster Drugs.

The new kid on the block is patient-level data. Unlike physician-level data that describes the wholesale activity of Dr. John Smith as writing say 50 scripts of Lipitor, patient-level data zooms in on the patients of Dr. John Smith and specifies patient by patient who actually gets Lipitor.

PHARMA-MKTING is an exclusive email network for pharmaceutical marketing professionals interested in the latest interactive technologies available for marketing. The network facilitates communication between members and recognized experts and leaders in interactive pharmaceutical marketing.